LCM
IMRX icon

Landscape Capital Management’s Immuneering IMRX Stock Holding History

Landscape Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,495
Closed -$356K – 765
2026
Q1 		$356K Sell
67,495
-14,854
-18% -$76.1K 0.02% 548
2025
Q4 		$542K Buy
+82,349
New +$529K 0.04% 464

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Landscape Capital Management's IMRX Position: Q2 2026 in Review

Landscape Capital Management sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 67,495 shares — an estimated $356K sold.

Landscape Capital Management first reported a position in IMRX in Q4 2025 and held it in 2 quarters. The position peaked at $542K in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Landscape Capital Management reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Landscape Capital Management sold 67,495 Immuneering shares in Q2 2026, an estimated $356K.
  • Landscape Capital Management first reported a position in Immuneering in Q4 2025 and held it in 2 quarters.
  • Landscape Capital Management's Immuneering position peaked at $542K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Landscape Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.